Kadcyla price too high says NICE

April 24, 2014 11:10 AM

Roche’s new breast cancer dug Kadcyla (trastuzumab emtansine) is too expensive for general use on the UK’s National Health Service, says NICE.

The National Institute for Health and Care Excellence (NICE) is currently appraising Kadcyla as a treatment option for people with HER2-positive breast cancer that has spread to other parts of the body, cannot be surgically removed and has stopped responding to initial treatment.

Draft guidance, published for consultation, says that despite some evidence of clinical efficacy, trastuzumab emtansine does not work well enough to justify its high cost and it therefore should not be recommended for routine NHS use.

Sir Andrew Dillon, NICE Chief Executive, said: “We had hoped that Roche would have recognised the challenge the NHS faces in managing the adoption of expensive new treatments by reducing the cost of Kadcyla to the NHS.

“This drug is already being funded through the special Cancer Drugs Fund. Our job is to recommend whether it should transfer into the NHS budget. We are very aware of the importance that people place on life-extending cancer drugs and a decision not to recommend a cancer treatment for routine NHS funding is never taken lightly. We apply as much flexibility as we can in approving new treatments, but the reality is that given its price and what it offers to patients, it will displace more health benefit which the NHS could achieve in other ways, than it will offer to patients with breast cancer.”

The independent Appraisal Committee, which develops recommendations on behalf of NICE, considered evidence from the manufacturer, doctors and patient experts. It heard that trastuzumab emtansine is most likely to be given as a ‘second-line’ treatment and could potentially help to extend life by nearly 6 months compared with the treatment combination of lapatinib plus capecitabine. However, a course of treatment with trastuzumab emtansine is expected to cost £90,831 per patient – tens of thousands of pounds more than other currently available second-line treatments. Considering the high cost of the drug, the committee concluded that it could not recommend trastuzumab emtansine as a cost-effective use of NHS money.

Sir Andrew continued: “We hope the manufacturer will act in the best interests of patients and use this consultation period to look again at their evidence and consider if there is more they can do.”

Consultees, including the manufacturer, healthcare professionals and members of the public are able to comment on the draft recommendations via the NICE website until Monday 19 May 2014. All comments received during this consultation will be considered by the committee and a second draft of the guidance will then be published. If there are no objections at that stage, NICE will publish final guidance to the NHS. Until then, NHS bodies should make decisions locally on the funding of specific treatments.

 

Source: NICE

 

Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)


Latest News on Biosimilar News

Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?

Suggestions?

Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!